Could the HALP score serve as a biomarker of bronchiectasis exacerbation?

Tuberk Toraks. 2024 Mar;72(1):9-15. doi: 10.5578/tt.202401811.

Abstract

Introduction: Bronchiectasis is a chronic inflammatory lung disease and patients may occasionally experience acute exacerbations. Our study aims to determine the relationship between exacerbation periods and HALP (hemoglobin, albumin, lymphocyte, platelet) scores in patients with bronchiectasis.

Materials and methods: Adult patients diagnosed with bronchiectasis and followed up in our clinic between 02.2020-12.2022 were retrospectively evaluated. After the examinations, the effect of bronchiectasis exacerbation on the HALP score was investigated.

Result: A total of 84 patients diagnosed with non-cystic fibrosis bronchiectasis were included in our study. 42 of the patients were male (50%), and 42 were female. The average age of all patients was 52.37 ± 16.2. 35 patients (41.7%) were in the exacerbation period, and 49 patients (58.3%) were in the stable period. The median values of leukocytes, neutrophils, and C-reactive protein (CRP) were significantly higher in patients during the exacerbation period compared to the stable period (respectively p= 0.00, p= 0.00, p= 0.00). The average values of FEV1% and FVC% in patients during the exacerbation period were significantly lower compared to the stable period (p= 0.03, p= 0.00, respectively). The HALP score was significantly lower in patients during the exacerbation period compared to the stable period (p= 0.00). A significant negative correlation was found between the HALP score and leukocytes, neutrophils, and CRP (p= 0.00, p= 0.00, p= 0.00, respectively). Also, a significant positive correlation was found between the HALP score and FEV1% and FVC% (p= 0.00, p= 0.00, respectively).

Conclusions: Our study revealed that the HALP score is associated with infectious and pulmonary functional parameters in bronchiectasis patients in the exacerbation period. We propose that the HALP score could serve as a valuable biomarker during exacerbations.

MeSH terms

  • Adult
  • Aged
  • Biomarkers* / blood
  • Bronchiectasis* / blood
  • C-Reactive Protein / analysis
  • Disease Progression*
  • Female
  • Hemoglobins / analysis
  • Humans
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Platelet Count
  • Respiratory Function Tests
  • Retrospective Studies
  • Severity of Illness Index

Substances

  • Biomarkers
  • C-Reactive Protein
  • Hemoglobins